Figure 2C shows that BC patients with TRNT1 alterations had poorer progression‐free (p = 0.0322) and disease‐specific survival (p = 0.0369) compared to those without, while no significant difference in disease‐free (p = 0.787) and overall survival (p = 0.220). This evidence concerns the gene TRNT1 and breast cancer.